Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of...
-
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases...
-
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the...
-
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
-
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
-
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
-
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...
-
PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
-
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
-
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...